As of the publication, the stock has fallen more than 10%, trading at $262.37.
According to the intelligence financial APP, on Tuesday, Amgen (AMGN.US) stock price plummeted, with a drop of over 10% as of press time, trading at $262.37. Prior to this, the company stated that its experimental obesity treatment drug MariTide can help obese patients to lose an average of up to 20% of their body weight after one year of use, however, this result has failed to satisfy the market. Wall Street analysts have stated that they expect MariTide to be able to reduce weight by at least 20% in Phase II trials, with some hoping for a maximum weight loss of 25%.
